Literature DB >> 8761369

TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.

S Gretarsdottir1, L Tryggvadottir, J G Jonasson, H Sigurdsson, K Olafsdottir, B A Agnarsson, H Ogmundsdottir, J E Eyfjörd.   

Abstract

The aim of this investigation was to examine the possibility of analysing TP53 mutations in archival paraffin-embedded material with the constant denaturant gel electrophoresis (CDGE) method. We extracted DNA from 193 archival primary breast carcinoma samples, diagnosed in 1981-83; further analysis was possible for 186 of these. TP53 mutations in exons 5-8 were detected with CDGE in 30 samples (16.1%) and 17 of these mutations were confirmed by sequencing. Immunohistochemistry demonstrated TP53 nuclear accumulation in 58 tumours (31%). A strong association between the presence of TP53 mutations and TP53 immunostaining was observed (P < 0.001). Our mutation and immunohistochemistry results are in agreement with other findings based on fresh tumour tissue. TP53 abnormalities were significantly related to high S-phase fraction, low oestrogen receptor (ER) content and high tumour grade. Survival of patients with TP53 abnormalities, in the group as a whole, did not differ from patients with normal TP53. Our study did, however, show that patients with abnormal TP53 had a significantly shorter post-recurrence survival (P = 0.005) than patients with normal TP53.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761369      PMCID: PMC2074687          DOI: 10.1038/bjc.1996.400

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Time to abandon TNM staging of breast cancer?

Authors:  L C Barr; M Baum
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications.

Authors:  Q Chou; M Russell; D E Birch; J Raymond; W Bloch
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

4.  The p53-dependent gamma-ray response of GADD45.

Authors:  Q Zhan; I Bae; M B Kastan; A J Fornace
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

5.  Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.

Authors:  A L Børresen; E Hovig; B Smith-Sørensen; D Malkin; S Lystad; T I Andersen; J M Nesland; K J Isselbacher; S H Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

6.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

7.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.

Authors:  M L Smith; I T Chen; Q Zhan; I Bae; C Y Chen; T M Gilmer; M B Kastan; P M O'Connor; A J Fornace
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

Review 8.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.

Authors:  K Niwa; M Itoh; T Murase; S Morishita; N Itoh; H Mori; T Tamaya
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more
  6 in total

1.  p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.

Authors:  Crystal E Berger; Yingjuan Qian; Gang Liu; Hongwu Chen; Xinbin Chen
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

Review 2.  The p53-estrogen receptor loop in cancer.

Authors:  C Berger; Y Qian; X Chen
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

3.  Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer.

Authors:  K A Scott; R A Walker
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.

Authors:  P D Pharoah; N E Day; C Caldas
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

5.  Estradiol stabilizes p53 protein in breast cancer cell line, MCF-7.

Authors:  Naoki Okumura; Shigehira Saji; Hidetaka Eguchi; Shin-ichi Hayashi; Shigetoyo Saji; Shigeru Nakashima
Journal:  Jpn J Cancer Res       Date:  2002-08

6.  Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.

Authors:  Xia Li; Jie Wei; Yixiong Liu; Peifeng Li; Linni Fan; Yingmei Wang; Mingyang Li; Danhui Zhao; Zhou Yu; Jing Ye; Ying Guo; Qingguo Yan; Shuangping Guo; Zhe Wang
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.